Citations

Clear

2429 citation(s) found for "Shah, M".

The Genomic Landscape and Treatment Outcomes Associated with CDKN2A/MTAP Loss in Patients with Non–Small Cell Lung Cancer
Vokes, Natalie I. , Symons, Jessica L. , Rhead, Brooke , Hong, Lingzhi , Shah, Pooja A. , Lai, Zhongwu , Zhu, Zhou , Treviño, Santiago , Iorgulescu, J. Bryan , Wu, Jia , Leventakos, Konstantinos , Zhu, Zhou , Bryan, Julian , Zhang, Jianjun , Gibbons, Don L , Heymach, John V , Stewart, Ross , Iyer, Sonia , Leventakos, Konstantinos , Fragkogianni, Stamatina , Chao, Calvin Y. , Rodon, Jordi , Zhang, Jianjun , Heymach, John V. , Fragkogianni, Stamatina , Vokes, N. , Wu, Jia

Mayo Clinic

Clinical Cancer Research | July 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF14

10.1158/1078-0432.ccr-26-0771 | PMID 42507545 Get It

Abstract Purpose: Homozygous deletion of the 9p21 locus, containing CDKN2A/B and MTAP [CDKN2A/MTAP deletion (CMdel)], underlies emerging therapeutic strategies, including PRMT5/MAT2A inhibition. The clinicogenomic context and treatment outcome associations of CMdel in non–small cell lung cancer (NSCLC) remain incompletely defined. Experimental Design: We analyzed Tempus Lens records with paired DNA (xT) and RNA (xR) sequencing. After quality filtering (purity ≥40%), 16,947 patients were included in the primary dataset, and 10,996 were included in the validation dataset and stratified by deletion status [CMdel vs. CM wild-type (CMwt)]. IFN status was defined by IFN-kappa (IFNK) expression [log2(TPM + 1)] using the 25th percentile of CMwt as the threshold. Immune composition was inferred by quanTIseq. First-line regimens were grouped as immune checkpoint inhibitor (ICI) monotherapy, ICI chemotherapy, chemotherapy, or tyrosine kinase inhibitors (TKI). Best response and time to next treatment (TTNT) with risk-set adjustment and 18-month truncation were assessed. Results: CMdel occurred in 11.7% (n = 1,991) and 15% (n = 1,676), respectively, and was enriched in mucinous histology, stage IV disease, and never smokers. CMdel was associated with EGFR, TERT, and SMARCA4 alterations, whereas CMwt was associated with RB1, SETD2, and ARID2. More than 50% of CMdel tumors harbored targetable coalterations, enriched in EGFR/ALK/RET and relatively depleted in KRAS. CMdel tumors exhibited lower PD-L1, mutation burden, and immune infiltration. TTNT did not differ by CM status for ICI monotherapy or TKI but was shorter in CMdel for ICI chemotherapy and chemotherapy. Discordant and broad deletions were less common and had weaker TTNT association. IFNK-low expression marked immune-excluded subgroups with worse treatment outcomes. Conclusions: CDKN2A/MTAP loss defines a prevalent, genomically distinct NSCLC subset enriched in actionable drivers. CMdel associates with worse outcomes to ICI/chemotherapy-containing regimens. These findings highlight convergent biology at 9p21 and support biomarker-guided development of PRMT5/MAT2A inhibitors in MTAP-deleted NSCLC.
Risk‐Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients
Alsugair, Ali, Fathima, Saubia , Alhousani, Mohammad , Mariotti, E, Bolarinwa, Abiola , Faldu, Priyansh, Yousuf, Muhammad , Foran, James M. , Mangaonkar, Abhishek A. , Litzow, Mark, Sproat, Lisa, Palmer, Jeanne , Matin, Aasiya , Ayala, Ernesto , Slack, James L., Porrata, Luis, Khera, Nandita , Punwani, Nathan , Begna, Kebede H. , Pardanani, Animesh , Gangat, Naseema , Patnaik, Mrinal M. , Tefferi, Ayalew , Gauto‐Mariotti, Estefania , Alsugair, Ali , Alhousani, Mohammad M , Mariotti, Estefania Gauto , Csizmar, Clifford M. , Foran, James M , Mangaonkar, Abhishek A. , Litzow, Mark R. , Murthy, Hemant S , Matin, Aasiya , Ayala, Ernesto , Slack, James, Porrata, Luis , Iqbal, Madiha , Khera, Nandita , Kenderian, Saad Sirop , Chhabra, Saurabh , Pardanani, Animesh , Hogan, William J , Shah, Mithun V , Alkhateeb, Hassan B , Gangat, Naseema , Patnaik, Mrinal , Tefferi, Ayalew , Fathima, Saubia , Bolarinwa, Abiola B , Faldu, Priyansh, Murthy, Hemant S. , Iqbal, Madiha , Kenderian, Saad S. , Chhabra, Saurabh , Hogan, William J. , Shah, Meera , Alkhateeb, Hassan B.

Mayo Clinic

American Journal of Hematology | July 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70453 | PMID 42499183 Get It

ABSTRACT The recently published BLAST clinical risk model for chronic myelomonocytic leukemia (CMML) and its molecular version (BLAST‐Mol) differentiate low, intermediate, and high‐risk groups. The objective of the current retrospective study was to examine the survival impact of allogeneic stem cell transplant (ASCT) in a consecutive series of Mayo Clinic patients ( n = 775; 68% males, median age 71 years) with CMML, overall and adjusted for baseline BLAST/BLAST‐Mol risk categories. At a median follow‐up of 77 months, 151 (20%) patients underwent ASCT. Overall survival (OS) was longer in the ASCT compared to the non‐ASCT cohorts (median 77 vs. 28 months; p < 0.01). The significant difference in OS between the ASCT and non‐ASCT cohorts was retained after adjusting for BLAST clinical risk groups: high‐risk (median 50 vs. 14 months; p < 0.01), intermediate‐risk (81 vs. 28 months; p < 0.01), and low‐risk (111 vs. 65 months; p = 0.04), respectively. The same was mostly the case when OS comparison was adjusted for BLAST‐Mol with respective p values of < 0.01, < 0.01, and 0.08, respectively. Time‐dependent cox models confirmed the favorable survival impact of ASCT in the BLAST/BLAST‐Mol high‐ and intermediate‐risk groups. The current study highlights the benefit of ASCT for BLAST/BLAST‐Mol high‐ and intermediate‐risk groups in CMML and its potential to overcome the adverse impact of some high risk cytogenetic or molecular abnormalities. These observations support the early use of ASCT in CMML, ideally before BT and regardless of genetic characteristics.
An Artificial Intelligence Model for ECG-Based Prediction of Heart Failure with Preserved Ejection Fraction Diagnosis
Singh, Shekhar , Soliman, Elsayed Z., Kitzman, Dalane W., Herrington, David M. , Borlaug, B A, Davis, Robert L. , Shah, Sanjiv, Akbilgiç, Oğuz , Herrington, David M , Davis, Robert L , Akbilgic, Oguz , Karabayir, İbrahi̇m , Hayıt, Tolga , Soliman, Elsayed Z. , Kitzman, Dalane W. , Borlaug, Barry A.

Mayo Clinic

Journal of Cardiovascular Development and Disease | July 21, 2026 | Volume: 13 | Issue: 7 | Pages: 340

10.3390/jcdd13070340 | PMID 42505917 Get It

Background: Heart failure with preserved ejection fraction (HFpEF) accounts for over half of all heart failure (HF) cases and remains diagnostically challenging due to nonspecific symptoms and a lack of accessible noninvasive screening tools, leading to widespread underdiagnosis and delayed treatment. The electrocardiogram (ECG) is a low-cost, widely available tool that reflects myocardial electrical remodeling. We previously developed and externally validated an ECG-based artificial intelligence (ECG-AI) model capable of classifying ECGs into four categories: reduced ejection fraction (rEF), mid-range ejection fraction (mEF), HFpEF, and controls. In this study, we evaluate the ability of this ECG-AI model to predict future HFpEF diagnosis using real-world data from a large integrated health system. Methods: We applied the validated ECG-AI model to an independent cohort of 7713 patients from Wake Forest Baptist Health (WFBH), using one ECG per patient recorded before the clinical diagnosis of HFpEF. Model discrimination was evaluated across multiple prediction windows from six months up to ten years before diagnosis using the area under the receiver operating characteristic curve (AUC), with comparisons performed using DeLong’s test. Performance was also compared head-to-head with the H2FPEF score, a validated clinical score for HFpEF, in the subset of patients with complete data for score calculation. ECG-AI outputs were stratified into quartiles and evaluated using Kaplan–Meier survival analysis and multivariable Cox proportional hazards regression adjusted for demographics and major comorbidities. Results: Of the 7713 patients, 283 (3.7%) were subsequently diagnosed with HFpEF. The ECG-AI model achieved an AUC of 0.79 (95% CI, 0.72–0.86) using ECGs recorded within six months before diagnosis. Discrimination remained stable across prediction windows extending up to ten years before diagnosis (AUC range, 0.78–0.80; all DeLong p > 0.01 vs. the six-month window). Compared with the H2FPEF score, ECG-AI demonstrated superior discrimination, improving the AUC by 0.06–0.07 across the evaluated prediction windows. Patients in the highest ECG-AI risk quartile had an unadjusted hazard ratio (HR) of 11.18 (95% CI, 7.27–17.21; C-index, 0.75) and an adjusted HR of 6.60 (95% CI, 4.24–10.28; C-index, 0.82). Adding clinical covariates to ECG-AI improved the C-index by 0.07 and 0.09 for the five- and ten-year prediction windows, respectively. Conclusions: An independently validated ECG-AI model predicted incident HFpEF up to ten years before clinical diagnosis and outperformed the H2FPEF score using ECG alone, indicating that ECG-derived signatures precede clinical recognition of the syndrome. ECG-AI shows promise as a prognostic, risk-stratification tool to prioritize further evaluation; prospective validation and single-lead assessment are needed before screening or wearable deployment.
Temporal Trends and Predictors of Access Site Crossover During PCI in Contemporary Practice: A Report From the NCDR CathPCI Registry
Reynolds, E O R , Marks, Angel , Wojdyla, Daniel, Smilowitz, Nathaniel R. , Gilchrist, Ian C. , Gulati, Rajiv , Rao, Sunil V. , Reynolds, Eli , Shah, Binita , Marks, Angel , Wojdyla, Daniel , Smilowitz, Nathaniel R , Rymer, Jennifer A , Gilchrist, Ian C , Gulati, Rajiv , Rao, Sunil V , Shah, Binita

Mayo Clinic

Circulation: Cardiovascular Interventions | July 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circinterventions.126.016673 | PMID 42473791 Get It

BACKGROUND: Randomized trials comparing radial and femoral access report access site crossover rates of 3% to 9% for radial access and 1% to 3% for femoral access. However, contemporary real-world crossover rates are not well characterized. The aim was to evaluate contemporary trends and predictors of vascular access site crossover during percutaneous coronary intervention (PCI). METHODS: We analyzed index PCI procedures recorded in the National Cardiovascular Data Registry CathPCI Registry from 2018 to 2024. Access site crossover was identified using documented access data, with radial-to-femoral crossover inferred when the final successful access site was femoral. Temporal trends and clinical predictors of crossover were examined. Operator experience was assessed using cumulative total and radial PCI volumes from 2011 to 2024 as captured in CathPCI Registry versions 4 and 5. RESULTS: Among 3 861 790 index PCIs, 192 902 (5.0%) involved access site crossover, with a modest increase over time. Radial-to-femoral crossover accounted for 81.2% of crossover events. Factors independently associated with crossover included older age, female sex, higher body mass index, and peripheral vascular disease. Operators with the lowest total PCI volume and the lowest radial PCI volume experienced the highest crossover rates. Notably, operators with low radial PCI volume demonstrated a substantial decline in radial-to-femoral crossover over the study period. CONCLUSIONS: In contemporary clinical practice, access site crossover rates are consistent with those reported in randomized trials. Although crossover occurs more frequently among lower-volume operators, rates decline with increasing operator experience, supporting the presence of a radial access learning curve and improvement in procedural performance over time.
Acute Myeloid Leukemia Subtype‐Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy
Bolarinwa, Abiola , Al‐Kali, Aref , Mangaonkar, Abhishek A. , Saliba, Antoine N. , Hefazi, Mehrdad , Matin, A, Elliott, Michelle A. , Litzow, Mark R. , Hogan, William J. , Patnaik, Mrinal M. , Pardanani, Animesh , Foran, James M. , Punwani, Nathan , Palmer, Jeanne , Sproat, Lisa Z., Reichard, Kaaren K., He, Rong , Viswanatha, David S., Zepeda‐Mendoza, Cinthya , Gangat, Naseema , Begna, Kebede H. , Tefferi, Ayalew , Saliba, Antoine N. , Alkhateeb, Hassan B , Mangaonkar, Abhishek A. , Saliba, Antoine N , Hefazi, Mehrdad , Elliott, Michelle , Litzow, Mark R. , Hogan, William J , Shah, Mithun V , Patnaik, Mrinal , Pardanani, Animesh , Foran, James M , Badar, Talha , Murthy, Hemant S , Chen, Dong , He, Rong , Zepeda-Mendoza, Cinthya J , Gangat, Naseema , Tefferi, Ayalew , Saliba, Antoine N , Bolarinwa, Abiola B , Alkhateeb, Hassan B. , Shah, Meera , Badar, Talha , Murthy, Hemant S. , Chen, Dong , Reichard, Kaaren K.

Mayo Clinic

American Journal of Hematology | July 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70443 | PMID 42470254 Get It

ABSTRACT We examined the prognostic value of routine NGS data in newly diagnosed acute myeloid leukemia (AML) treated with intensive (7 + 3 backbone) induction, specified by AML subtype. A contemporary (2015–2025) series of 545 Mayo Clinic patients (median age 56 years, females 44%) was considered. Median follow‐up was 49 months with 341 (63%) allogeneic hematopoietic stem cell transplantations (AHSCT) recorded. AML subtypes included core‐binding factor (CBF; N = 72; 13%), primary non‐CBF ( N = 403; 74%), post‐myelodysplastic syndromes (MDS) or post‐myelodysplastic/myeloproliferative neoplasms (post‐MDS‐MDS/MPN; N = 28; 5%), post‐MPN ( N = 15; 3%), and therapy‐related (t‐AML; N = 27; 5%). Corresponding complete remission rates, with/without count recovery (CR/CRi), were 89%, 76%, 64%, 27%, and 78% ( p < 0.01) and 5‐year transplant‐censored survival rates 68%, 57%, 21%, 0%, and 55% ( p < 0.01). In multivariable analyses, the prognostic value of specific mutations was mostly limited to primary non‐CBF AML where adverse karyotype (OR 1.9; p = 0.04) predicted inferior and FLT3 ‐ITD (OR 0.4; p < 0.01) or NPM1 MUT / FLT3 WT (OR 0.1; p < 0.01) superior CR/CRi while KRAS MUT (HR 8.8; p < 0.01), TP53 MUT (HR 5.4; p < 0.01), and TET2 MUT (HR 2.3; p = 0.01) predicted inferior and NPM1 MUT / FLT3 WT (HR 0.3; p = 0.01) superior survival. Prognostication in intensively‐treated AML should start with subtype specification and recognition of the limited value of NGS in non‐primary AML. Post‐MPN AML is particularly associated with dismal outcomes and should be prognostically distinguished from post‐MDS‐MDS/MPN AML. In primary non‐CBF AML, in addition to previously established risk factors, the favorable impact of FLT3 ‐ITD on achieving CR/CRi and the unfavorable impact of KRAS MUT and TET2 MUT on transplant‐censored survival were noted and require confirmation from additional studies.
Outcomes of Underwater Endoscopic Mucosal Resection for Giant Colorectal Polyps: A Multicenter Study
Karna, Rahul , Wilson, Natalie , Seid, Amir S, Larsen, Kaylee, Enke, Thomas , Hassam, Ali, Kumar, Anand R, Shah, Shawn L, Zhao, Joy, Choi, Alyssa Y, Issa, Danny, Saeed, Ahmed, Phan, Jennifer, Mosko, Jeffrey D, Dang, Frances, Westanmo, Anders, Reinink, Andrew, Samarasena, Jason B, Shaukat, Aasma, Mosko, Jeffrey D. , Bilal, Mohammad , Karna, Rahul , Larsen, Kaylee, Enke, Thomas , Choi, Alyssa Y. , Issa, Danny , Saeed, Ahmed, Phan, Jennifer, Dang, Frances , Westanmo, Anders , Reinink, Andrew R. , Samarasena, Jason , Shaukat, Aasma , Bilal, Mohammad , Wilson, Natalie

Mayo Clinic

Endoscopy International Open | July 15, 2026 | Volume: 14 | Issue: CP | Pages: No page available

10.1055/a-2910-5182 | PMID 42592233 Get It

Abstract Introduction Underwater endoscopic mucosal resection (uEMR) technique has gained popularity for removal of large non-pedunculated colorectal polyps (LNPCPs) due to high en-bloc resection rates and lower recurrence rates. However, there is no information regarding outcomes of uEMR for giant colorectal polyps. Therefore, we aimed to evaluate the outcomes of uEMR for giant colorectal polyps across multiple centers in North America. Methods We conducted a multicenter retrospective study of adults with giant colorectal polyps undergoing uEMR between January 2019 and November 2025. Giant colorectal polyps were defined as LNPCPs ≥40 mm. Primary outcomes were technical success and rate of recurrent adenoma. Secondary outcomes were severe adverse events (SAEs) and predictors of technical success, recurrence, and SAEs. Results A total of 137 polyps, with mean polyp size 47.6 mm were included. Majority of the lesions were located in right colon (61%, n = 83) with the most common histopathology being high-grade dysplasia (HGD) (31.4%, n = 43). Technical success was achieved in 90.5% (n = 124) with en-bloc resection rate of 11.7% (n = 16). Polyp fibrosis (OR: 0.08) and HGD (OR: 0.15) were independent predictors of inability to achieve technical success. Of 92 (67.1%) patients with follow-up, recurrent polyp was present in 8.7% (n = 8). SAEs were noted in 9.5%, consisting of delayed bleeding (9.5%, n = 13), while no delayed perforation or post polypectomy syndrome was noted. Discussion Our study demonstrates that uEMR is technically feasible for the removal of giant colorectal polyps with an acceptable safety profile and recurrence rate.
Anatomy Curriculum and Teaching Insights From Medical Students in the United Kingdom: A National Survey
Kiew, Cheuk Ying Kyleen , Shah, Anuska , Mahmood, Ameen, Rehman, Umar , Fareed, Fay Fathima Imtiaz, Chhatwal, Karanjot, Arab, Sammy, Sarwar, Mohammad Sohaib, Pafitanis, Georgios, Brennan, Peter A., Collaborators, UKPRC, Hadjiandreou, Michalis , Kiew, Cheuk Ying Kyleen , Mahmood, Ameen R. , Rehman, Umar , Fareed, Fay Fathima Imtiaz , Chhatwal, Karanjot , Arab, Sammy , Sarwar, Mohammad Sohaib , Pafitanis, Georgios , Brennan, Peter A

Mayo Clinic

Clinical Anatomy | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ca.70185 | PMID 42452997 Get It

ABSTRACT Undergraduate anatomy teaching in the UK has been progressively compressed, with reduced contact time and variable integration across medical programs. We examined final‐year medical students' perceptions of anatomy teaching, focusing on total contact hours, longitudinal continuity, and exposure to traditional and emerging teaching modalities. A national cross‐sectional survey was distributed to final‐year students across 40 UK medical schools between December 2024 and February 2025. Satisfaction with anatomy teaching, perceived importance of anatomy for future practice, contact hours, continuity across program years, and exposure to specific teaching modalities and technologies were assessed. Comparative analyses used non‐parametric tests and ANOVA with post hoc testing where appropriate. 628 students responded. Dissatisfaction was greatest for teaching quantity and continuity, whereas breadth, depth, and quality were rated more favourably. Students receiving more than 200 h of anatomy teaching reported significantly higher satisfaction than those receiving fewer than 200 h ( p < 0.001). Satisfaction also varied by continuity pattern, with teaching delivered continuously over three or more years associated with higher satisfaction than shorter or non‐continuous models ( p < 0.01). Cadaveric dissection was the most preferred modality, but higher satisfaction was associated with exposure to selected adjuncts, particularly 3D imaging software and 3D printed models (both p < 0.001); VR/AR showed no significant association. Perceived importance of anatomy differed by intended specialty, with students interested in surgery rating anatomy as most important ( p < 0.0001). Student dissatisfaction with UK undergraduate anatomy teaching appears to stem less from content coverage than from insufficient teaching time and poor longitudinal integration. Anatomy should be protected as a multi‐year component of the curriculum, complemented by selectively integrated adjunctive tools rather than indiscriminate technology adoption.
Insulin autoimmune hypoglycemia unmasking monoclonal gammopathy in type 2 diabetes
Prasad, S. , Sharma, A K , Parmar, Vidhi, Jindal, Tanisha , Kothia, Darpan, Bavaria, Deep, Prasad, Sai , Kothia, Darpan

Mayo Clinic

JCEM Case Reports | July 13, 2026 | Volume: 4 | Issue: 8 | Pages: No page available

10.1210/jcemcr/luag190 | PMID 42438805 Get It

Abstract Insulin autoimmune syndrome (IAS), also known as Hirata disease, is a rare cause of spontaneous hypoglycemia due to circulating insulin autoantibodies, most commonly described in East Asian individuals and those exposed to sulfhydryl-containing drugs. We describe a 58-year-old South Asian man with type 2 diabetes mellitus who presented with recurrent fasting and postprandial hypoglycemia despite cessation of all glucose-lowering medications. A spontaneous episode confirmed Whipple triad: plasma glucose 38 mg/dL (SI: 2.1 mmol/L; reference range, 70-99 mg/dL [SI: 3.9-5.5 mmol/L]), markedly elevated serum insulin at 156 µIU/mL (SI: 1083 pmol/L; reference range, 2.6-24.9 µIU/mL [SI: 18-173 pmol/L]), and C-peptide of 5.8 ng/mL (SI: 1.9 nmol/L; reference range, 0.5-2.0 ng/mL [SI: 0.17-0.66 nmol/L]), with a negative sulfonylurea screen and markedly elevated insulin autoantibody titers. Polyethylene glycol precipitation confirmed antibody-bound insulin sequestration. Workup identified IgG-kappa monoclonal gammopathy of undetermined significance as the probable precipitant. Dietary modification, oral glucocorticoids, and acarbose achieved near-complete resolution of hypoglycemia with declining autoantibody titers over 4 weeks. This case highlights the importance of considering IAS in unexplained hyperinsulinemic hypoglycemia and the need to screen for plasma cell dyscrasias in atypical presentations.
Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers
Shah, Priyanshi , Peersen, Anina, Sahai, Vaibhav , Mahipal, Amit , Naleid, Nikolas , Borad, Mitesh J. , Bekaii‐Saab, Tanios , Sonbol, Mohamad Bassam , Majeed, Umair , Babiker, Hani M. , O’Donnell, Conor, Malla, Midhun , Conboy, Caitlin B. , Fonkoua, Lionel Kankeu, Washburn, L. , Peterson, Nicole , Carr, Ryan M., Starlinger, P, Smoot, Rory, Warner, Susanne, Ilyas, Sumera L., Heimbach, Julie, Borad, Mitesh J , O'Donnell, Conor D J , Conboy, Caitlin B , Washburn, Leslie A , Halfdanarson, Thorvardur R , Peterson, Nicole , McWilliams, Robert R , Graham, Rondell P , Gores, Gregory J. , Roberts, Lewis R , Ou, Fang-Shu , Tran, Nguyen , Mahipal, Amit , Sonbol, Mohamad B , Bekaii-Saab, Tanios S , Babiker, Hani , Majeed, Umair , Sahai, Vaibhav , Peersen, Anina, Gupta, Garima , Fonkoua, Lionel Aurelien Kankeu , Hálfdánarson, Þorvarður R. , McWilliams, Robert R. , Carr, Ryan M , Graham, Rondell P. , Starlinger, Patrick, Warner, Susanne, Ilyas, Sumera I. , Gores, Gregory J. , Roberts, Lewis R. , Heimbach, Julie K. , Ou, Fang‐Shu , Tran, Nguyen H.

Mayo Clinic

JCO Precision Oncology | July 10, 2026 | Volume: 10 | Issue: 7 | Pages: No page available

10.1200/po-25-01156 | PMID 42430699 Get It

PURPOSE Deficient mismatch repair/microsatellite instability (dMMR, MSI-H) in biliary tract cancers (BTCs) is observed in 1%-5% of tumors. MSI-H across solid tumors has demonstrated durable response to immune checkpoint inhibitors (ICIs) regardless of the anatomic location. Here, we describe clinical outcomes and surgical conversion of MSI-H BTC treated with ICIs. Patients and Methods We conducted a multicenter, retrospective analysis of BTC patients with dMMR/MSI-H between 2017 and 2024 at Mayo Clinic, University of Michigan, and University Hospitals Seidman Cancer Center. Outcomes of interest were surgical resection rate, rate of pathologic response, 2-year overall survival (OS; time from initiation of treatment to death/last follow-up), and time to treatment discontinuation (TTD; time from initiation of treatment to cessation because of any cause). Analyses were descriptive. RESULTS Thirty patients with MSI-H BTC were identified: 19 with cholangiocarcinoma, three with gallbladder cancer, and 8 with BTC undefined. The median age at diagnosis was 61.5 years (range, 26-86). Twenty-six (86.7%) patients had advanced stage at diagnosis. Twenty-seven patients (90%) received first-line systemic therapy, and 13 (48.1%) continued onto second line. Six patients (23.1%) were restaged to resectable from advanced disease after ICI therapy and underwent resection; all remained recurrence-free at last follow-up. Of these six patients, 3 (50%) achieved a pathologic complete response. Among those receiving first-line therapy, the median TTD was 9.9 months (95% CI, 5.7 to 14.5 months) and the 2-year OS was 73% (95% CI, 56% to 94%). CONCLUSION ICI therapy in patients with MSI-H BTC demonstrated durable response and downstaged some BTC to a resectable stage. dMMR/MSI-H should be performed up-front to guide treatment decisions.